Laddar...
ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION
INTRODUCTION: Isocitrate dehydrogenase 1 and 2 mutations (mIDH1/2) occur in >70% of low-grade gliomas and secondary glioblastomas, and lead to genetic and epigenetic dysregulation, promoting tumorigenesis. AG-881 is an oral, potent, brain-penetrant inhibitor of mIDH1/2 under phase 1 clinical eval...
Sparad:
I publikationen: | Neuro Oncol |
---|---|
Huvudupphovsmän: | , , , , , , , , , , , , , , , , , , |
Materialtyp: | Artigo |
Språk: | Inglês |
Publicerad: |
Oxford University Press
2018
|
Ämnen: | |
Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216186/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.064 |
Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|